Interleukin-17A Inhibitor-induced Crohn's Disease/Behcet's Disease-like Lesions

被引：21

作者：

Shiga, Hisashi ^{[1
]}

Fukuda, Sho ^{[1
]}

Iijima, Katsunori ^{[1
]}

机构：

[1] Akita Univ, Grad Sch Med, Dept Gastroenterol & Neurol, Akita, Japan

来源：

INFLAMMATORY BOWEL DISEASES | 2017年 / 23卷 / 06期

关键词：

D O I：

10.1097/MIB.0000000000001142

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：E38 / E39

页数：2

相关论文

共 3 条

[1] Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience [J].

Freling, Estelle ;

Baumann, Cedric ;

Cuny, Jean-Francois ;

Bigard, Marc-Andre ;

Schmutz, Jean-Luc ;

Barbaud, Annick ;

Peyrin-Biroulet, Laurent .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (08) :1186-1196

[2] Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial [J].

Hueber, Wolfgang ;

Sands, Bruce E. ;

Lewitzky, Steve ;

Vandemeulebroecke, Marc ;

Reinisch, Walter ;

Higgins, Peter D. R. ;

Wehkamp, Jan ;

Feagan, Brian G. ;

Yao, Michael D. ;

Karczewski, Marek ;

Karczewski, Jacek ;

Pezous, Nicole ;

Bek, Stephan ;

Bruin, Gerard ;

Mellgard, Bjoern ;

Berger, Claudia ;

Londei, Marco ;

Bertolino, Arthur P. ;

Tougas, Gervais ;

Travis, Simon P. L. .

GUT, 2012, 61 (12) :1693-1700

[3] A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease [J].

Targan, Stephan R. ;

Feagan, Brian ;

Vermeire, Severine ;

Panaccione, Remo ;

Melmed, Gil Y. ;

Landers, Carol ;

Li, Dalin ;

Russell, Chris ;

Newmark, Richard ;

Zhang, Nan ;

Chon, Yun ;

Hsu, Yi-Hsiang ;

Lin, Shao-Lee ;

Klekotka, Paul .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (11) :1599-1607